Evidence map›Paper›PMID 42866025›Full record

ReviewFrontiers in physiology2026

The endocannabinoid signaling system in acute and chronic pancreatitis.

Alex Mabou Tagne, Jene Jamarillo, Lance R McMahon, Daniele Piomelli

Abstract readReview
In one paragraph

Review in Frontiers in physiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Alex Mabou TagneDepartment of Pharmaceutical Sciences, Jerry H. Hodge School of Pharmacy, Texas Tech University Health Sciences Center, Amarillo, TX, United States.
Jene JamarilloDepartment of Pharmaceutical Sciences, Jerry H. Hodge School of Pharmacy, Texas Tech University Health Sciences Center, Amarillo, TX, United States.
Lance R McMahonDepartment of Pharmaceutical Sciences, Jerry H. Hodge School of Pharmacy, Texas Tech University Health Sciences Center, Amarillo, TX, United States.
Daniele PiomelliDepartment of Anatomy and Neurobiology, University of California, Irvine, Irvine, CA, United States.

Funding

FAAH-regulated endocannabinoid signaling controls nociception in acute pancreatitisK01DK143205 · NIDDK · UNIVERSITY OF CALIFORNIA-IRVINE · PI Alex Mabou Tagne · 2025 to 2026
$322k
NIDDK NIH HHS K01 DK143205
6 · The paper itself

Abstract

The endocannabinoid system (ECS) is a ubiquitous lipid signaling network that regulates tissue homeostasis. Increasing evidence indicates that the ECS undergoes profound remodeling during pancreatic injury and may influence key pathological processes underlying acute pancreatitis (AP) and chronic pancreatitis (CP). Interest in this field has grown in parallel with increasing cannabis use among individuals with pancreatic disorders and the urgent need for alternatives to opioid-based pain management. Components of the ECS, including cannabinoid receptors, the endogenous ligands, and enzymes that mobilize such ligands, are widely expressed throughout both the exocrine and endocrine pancreas, where they contribute to the regulation of pancreatic function under physiological and pathological conditions. Studies demonstrate that AP and CP are associated with distinct alterations in cannabinoid receptor expression and endocannabinoid levels, yet the functional significance of these changes remains incompletely understood. Clinical evidence, however, remains limited and often conflicting. In this narrative review, we summarize current knowledge of ECS organization and function in the pancreas, examine how endocannabinoid signaling is altered during pancreatitis, and critically evaluate the therapeutic opportunities and challenges associated with targeting ECS pathways. We discuss an emerging hypothesis in which adaptive endocannabinoid signaling may contribute to resilience following pancreatic injury and propose that progressive disruption of this response could contribute to the transition from AP to CP.

Indexed as

2-arachidonoyl-sn-glycerolacute pancreatitisanandamidecannabinoidcannabischronic pancreatitis

Identifiers

PMID42866025
PMCPMC13655718

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.